Equities

Panacea Biotec Ltd

PANACEABIO:NSI

Panacea Biotec Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)314.09
  • Today's Change-16.54 / -5.00%
  • Shares traded28.69k
  • 1 Year change+93.88%
  • Beta0.9732
Data delayed at least 15 minutes, as of Sep 20 2024 10:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments1,5142,0755,493
Total Receivables, Net1,1141,0961,338
Total Inventory1,8272,0562,190
Prepaid expenses615253
Other current assets, total336404831
Total current assets4,8525,6839,906
Property, plant & equipment, net6,3486,1636,255
Goodwill, net------
Intangibles, net360259138
Long term investments1281.74804
Note receivable - long term690555202
Other long term assets201212
Total assets12,40712,71217,589
LIABILITIES
Accounts payable1,5371,7732,347
Accrued expenses102110170
Notes payable/short-term debt000
Current portion long-term debt/capital leases00.550.52
Other current liabilities, total1,4501,4355,246
Total current liabilities3,0883,3187,764
Total long term debt210202341
Total debt210202342
Deferred income tax2252040
Minority interest(38)(35)(30)
Other liabilities, total501587747
Total liabilities3,9864,2768,822
SHAREHOLDERS EQUITY
Common stock616161
Additional paid-in capital919919919
Retained earnings (accumulated deficit)7,3837,3987,745
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total575840
Total equity8,4208,4368,766
Total liabilities & shareholders' equity12,40712,71217,589
Total common shares outstanding616161
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.